Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2020

View Archived Issues

Mitochondria, interneurons, cognition link explored

Huntington's disease found to alter neurodevelopment

TTX-3360 selected as Triplet's first clinical candidate for repeat expansion disorders

Potent dual orexin OX1/2 receptor antagonist with improved PK profile for insomnia treatment

Phase Ib/II study of margetuximab + pembrolizumab in HER2-positive gastroesophageal adenocarcinoma

Characterization of real-time CAH degradation under pH environment of GI tract using microrheology

SOCS3 as a new therapeutic target in breast cancer

RO-7297089 demonstrates target engagement and safety in models of MM

CSF-1R as novel therapeutic target in 4T1 xenografts

SPV Therapeutics synthesizes new CDK inhibitors

Chinese investigators patent P2X3 receptor antagonists

Integral BioSciences discloses IDH1 mutant inhibitors

Dana-Farber Cancer Institute describes CDK7 inhibitors

Janssen Pharmaceutica and Johnson & Johnson present FGFR3 inhibitors

Signs of efficacy seen with DC-based cryoimmunotherapy ACT-2001 in mCRPC

Harbour BioMed presents CD73-targeting antibody HBM-1007 for immuno-oncology therapy

FibroGenesis' PneumoBlast induces reduction of lung fibrosis

New phase I/II trial explores use of DNL-310 for pediatric patients with Hunter's syndrome

TAK-676 studied alone and with pembrolizumab in new phase I study for advanced solid tumors

First phase II study of Lyme disease vaccine candidate VLA-15 meets endpoints

AdAlta begins treatment in phase I study of AD-214 for interstitial lung disease

Inotrem cleared to begin phase IIa study of nangibotide in patients with COVID-19

PTC initiates phase II/III study of PTC-299 in hospitalized participants with COVID-19

Gan & Lee opens phase Ib/II study of GLR-2007 in advanced solid tumors

UCB begins first-in-human evaluation of UCB-8600